Cargando…
Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again
Multiple myeloma (MM) is an incurable hematologic malignancy characterized by a multistep evolutionary pathway, with an initial phase called monoclonal gammopathy of undetermined significance (MGUS), potentially evolving into the symptomatic disease, often preceded by an intermediate phase called “s...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844382/ https://www.ncbi.nlm.nih.gov/pubmed/36648882 http://dx.doi.org/10.3390/hematolrep15010004 |
_version_ | 1784870642393284608 |
---|---|
author | Plano, Federica Corsale, Anna Maria Gigliotta, Emilia Camarda, Giulia Vullo, Candida Di Simone, Marta Shekarkar Azgomi, Mojtaba Speciale, Maria Carlisi, Melania Caccamo, Nadia Dieli, Francesco Meraviglia, Serena Siragusa, Sergio Botta, Cirino |
author_facet | Plano, Federica Corsale, Anna Maria Gigliotta, Emilia Camarda, Giulia Vullo, Candida Di Simone, Marta Shekarkar Azgomi, Mojtaba Speciale, Maria Carlisi, Melania Caccamo, Nadia Dieli, Francesco Meraviglia, Serena Siragusa, Sergio Botta, Cirino |
author_sort | Plano, Federica |
collection | PubMed |
description | Multiple myeloma (MM) is an incurable hematologic malignancy characterized by a multistep evolutionary pathway, with an initial phase called monoclonal gammopathy of undetermined significance (MGUS), potentially evolving into the symptomatic disease, often preceded by an intermediate phase called “smoldering” MM (sMM). From a biological point of view, genomic alterations (translocations/deletions/mutations) are already present at the MGUS phase, thus rendering their role in disease evolution questionable. On the other hand, we currently know that changes in the bone marrow microenvironment (TME) could play a key role in MM evolution through a progressive shift towards a pro-inflammatory and immunosuppressive shape, which may drive cancer progression as well as clonal plasma cells migration, proliferation, survival, and drug resistance. Along this line, the major advancement in MM patients’ survival has been achieved by the introduction of microenvironment-oriented drugs (including immunomodulatory drugs and monoclonal antibodies). In this review, we summarized the role of the different components of the TME in MM evolution from MGUS as well as potential novel therapeutic targets/opportunities. |
format | Online Article Text |
id | pubmed-9844382 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98443822023-01-18 Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again Plano, Federica Corsale, Anna Maria Gigliotta, Emilia Camarda, Giulia Vullo, Candida Di Simone, Marta Shekarkar Azgomi, Mojtaba Speciale, Maria Carlisi, Melania Caccamo, Nadia Dieli, Francesco Meraviglia, Serena Siragusa, Sergio Botta, Cirino Hematol Rep Review Multiple myeloma (MM) is an incurable hematologic malignancy characterized by a multistep evolutionary pathway, with an initial phase called monoclonal gammopathy of undetermined significance (MGUS), potentially evolving into the symptomatic disease, often preceded by an intermediate phase called “smoldering” MM (sMM). From a biological point of view, genomic alterations (translocations/deletions/mutations) are already present at the MGUS phase, thus rendering their role in disease evolution questionable. On the other hand, we currently know that changes in the bone marrow microenvironment (TME) could play a key role in MM evolution through a progressive shift towards a pro-inflammatory and immunosuppressive shape, which may drive cancer progression as well as clonal plasma cells migration, proliferation, survival, and drug resistance. Along this line, the major advancement in MM patients’ survival has been achieved by the introduction of microenvironment-oriented drugs (including immunomodulatory drugs and monoclonal antibodies). In this review, we summarized the role of the different components of the TME in MM evolution from MGUS as well as potential novel therapeutic targets/opportunities. MDPI 2023-01-09 /pmc/articles/PMC9844382/ /pubmed/36648882 http://dx.doi.org/10.3390/hematolrep15010004 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Plano, Federica Corsale, Anna Maria Gigliotta, Emilia Camarda, Giulia Vullo, Candida Di Simone, Marta Shekarkar Azgomi, Mojtaba Speciale, Maria Carlisi, Melania Caccamo, Nadia Dieli, Francesco Meraviglia, Serena Siragusa, Sergio Botta, Cirino Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again |
title | Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again |
title_full | Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again |
title_fullStr | Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again |
title_full_unstemmed | Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again |
title_short | Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again |
title_sort | monoclonal gammopathies and the bone marrow microenvironment: from bench to bedside and then back again |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844382/ https://www.ncbi.nlm.nih.gov/pubmed/36648882 http://dx.doi.org/10.3390/hematolrep15010004 |
work_keys_str_mv | AT planofederica monoclonalgammopathiesandthebonemarrowmicroenvironmentfrombenchtobedsideandthenbackagain AT corsaleannamaria monoclonalgammopathiesandthebonemarrowmicroenvironmentfrombenchtobedsideandthenbackagain AT gigliottaemilia monoclonalgammopathiesandthebonemarrowmicroenvironmentfrombenchtobedsideandthenbackagain AT camardagiulia monoclonalgammopathiesandthebonemarrowmicroenvironmentfrombenchtobedsideandthenbackagain AT vullocandida monoclonalgammopathiesandthebonemarrowmicroenvironmentfrombenchtobedsideandthenbackagain AT disimonemarta monoclonalgammopathiesandthebonemarrowmicroenvironmentfrombenchtobedsideandthenbackagain AT shekarkarazgomimojtaba monoclonalgammopathiesandthebonemarrowmicroenvironmentfrombenchtobedsideandthenbackagain AT specialemaria monoclonalgammopathiesandthebonemarrowmicroenvironmentfrombenchtobedsideandthenbackagain AT carlisimelania monoclonalgammopathiesandthebonemarrowmicroenvironmentfrombenchtobedsideandthenbackagain AT caccamonadia monoclonalgammopathiesandthebonemarrowmicroenvironmentfrombenchtobedsideandthenbackagain AT dielifrancesco monoclonalgammopathiesandthebonemarrowmicroenvironmentfrombenchtobedsideandthenbackagain AT meravigliaserena monoclonalgammopathiesandthebonemarrowmicroenvironmentfrombenchtobedsideandthenbackagain AT siragusasergio monoclonalgammopathiesandthebonemarrowmicroenvironmentfrombenchtobedsideandthenbackagain AT bottacirino monoclonalgammopathiesandthebonemarrowmicroenvironmentfrombenchtobedsideandthenbackagain |